Stocky turns companies like PHARMA MAR, S.A. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Hold. PHM.MC shows solid growth credentials (70/100 Compounder Score, driven by consistent revenue expansion) but faces material structural vulnerabilities—a financial buffer is its only moat against cyclical headwinds. Leadership alignment is modest (59/100), and valuation at 18.2× forward earnings offers limited margin of safety given execution and macro risks.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for PHARMA MAR, S.A.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 66/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates PHARMA MAR, S.A. (PHM.MC) at 66/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. PHM.MC shows solid growth credentials (70/100 Compounder Score, driven by consistent revenue expansion) but faces material structural vulnerabilities—a financial buffer is its only moat against cyclical headwinds. Leadership alignment
PHM.MC's current Stocky Verdict is 66/100, placing it in the "Hold" band. This composite combines a 70/100 Compounder score, 59/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for PHARMA MAR, S.A. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
PHARMA MAR, S.A. scores 59/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
PHARMA MAR, S.A.'s Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to PHARMA MAR, S.A..
Sign up free and unlock the full analysis on PHM.MC — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for PHM.MC in the app.
